Teva   3Q Revenues: $4.8 billion (-5%) 3Q Earnings: $116 million (-87%) YTD Revenues: $14.8 billion (-2%) YTD Earnings: $1.1 billion (+52%) Comments: Specialty medicines revenue in the quarter was flat at $2.2 billion. Global sales of Copaxone were $1.1 billion, down 2%. Azilect revenues were $92 million, down 11%. Sales of respiratory products were $285 million, up 31% driven by ProAir ($149 million, up 34%). Generic revenues were $2.2 billion in the quarter, down 9% mainly from a...